{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022628","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.570668+00:00","generated_at":"2026-06-22T05:30:45.786450+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vaxcyte reports positive VAX-24 Phase 1/2 data; Q3 net loss $57.9M, cash $366.2M plus $650.7M offering","bullets":["Q3 net loss $57.9M (vs $26.6M YoY); R&D $47.7M (up from $20.4M) on Phase 3/IND activities.","Cash $366.2M at Sep 30, plus ~$650.7M net from Oct follow-on offering.","VAX-24 Phase 1/2 met endpoints; at 2.2mcg dose, non-inferiority for all 20 PCV20 serotypes, 16 higher, 4 superior.","Expect VAX-24 Phase 2 data in 65+ in H1 2023; infant IND in H1 2023; VAX-XP IND in H2 2023.","Appointed Mark Wiggins as CBO and Jakub Simon as CMO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022628","json":"https://secwatch.observer/filing/0000950170-22-022628.json","markdown":"https://secwatch.observer/filing/0000950170-22-022628.md","text":"https://secwatch.observer/filing/0000950170-22-022628.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000095017022022628/0000950170-22-022628-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000095017022022628/pcvx-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:30:45.786450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c585dbb6c00b10584a9b8d6800d63ddbe48a7fe2","claim":"Vaxcyte, Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"On November 7, 2022, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649094/000095017022022628/0000950170-22-022628-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}